https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-endometrial-cancer-likelihood-of-approval/
BGB-10188 by BeiGene for Endometrial Cancer: Likelihood of Approval
Dec 30, 2024 - BGB-10188 is under clinical development by BeiGene and currently in Phase II for Endometrial Cancer.
endometrial cancerbgb10188beigenelikelihood
https://arxiv.org/abs/2603.10188
[2603.10188] ARCHE: Autoregressive Residual Compression with Hyperprior and Excitation
Abstract page for arXiv paper 2603.10188: ARCHE: Autoregressive Residual Compression with Hyperprior and Excitation
260310188archeautoregressiveresidual
https://www.eprints.org/eptech/msg10188.html
Message: #10188 | EPrints Technical Mailing List
message10188eprintstechnicalmailing
https://feedly.com/cve/CVE-2020-10188
CVE-2020-10188 - Exploits & Severity - Feedly
utility.c in telnetd in netkit telnet through 0.17 allows remote attackers to execute arbitrary code via short writes or urgent data, because of a buffer...
cve202010188exploitsseverity
https://www.canberra.edu.au/unit/10188/2/2027
Built Environment Technology 2 (10188) - University of Canberra
built environmenttechnology 2university of10188canberra
https://www.thermofisher.com/antibody/product/TGFBI-BIGH3-Antibody-Polyclonal/10188-1-AP
TGFBI / BIGH3 Polyclonal Antibody | Invitrogen (10188-1-AP)
Detect TGFBI / BIGH3 in IHC (P), IP, WB, Flow, ICC/IF. Reacts with Mouse, Rabbit. Cited in 60 publications. Catalog # 10188-1-AP
polyclonal antibodytgfbibigh3invitrogen10188